| OR (95% CI) | P* |
---|---|---|
Model 1 (baseline Ox-LDL) | ||
 Prestroke Statins use | ||
  Mortality | 0.38(0.16–0.91) | 0.031 |
  Major disability (mRs3–5) | 0.38 (0.15–0.99) | 0.047 |
  Major disability (mRs3–5) + death | 0.31(0.17–0.74) | 0.009 |
 NIHSS score | ||
  Mortality | 1.18(1.10–1.26) | < 0.001 |
  Major disability (mRs3–5) | 1.17(1.06–1.30) | 0.003 |
  Major disability (mRs3–5) + death | 1.20(1.10–1.29) | < 0.001 |
Model 2(3-month Ox-LDL levels) | ||
 Prestroke Statins use | ||
  Mortality | 0.36(1.15–0.87) | 0.023 |
  Major disability (mRs3–5) | 0.38(0.15–0.95) | 0.038 |
  Major disability (mRs3–5) + death | 0.27(0.11–0.64) | 0.003 |
 NIHSS score | ||
  Mortality | 1.18(1.11–1.27) | < 0.001 |
  Major disability (mRs3–5) | 1.17(1.06–1.30) | 0.003 |
  Major disability (mRs3–5) + death | 1.19(0.10–1.29) | < 0.001 |